BRPI0919065A2 - anticorpos monoclonais anti-claudin-1 para a inibição de infecção por virus de hepatite c - Google Patents

anticorpos monoclonais anti-claudin-1 para a inibição de infecção por virus de hepatite c

Info

Publication number
BRPI0919065A2
BRPI0919065A2 BRPI0919065A BRPI0919065A BRPI0919065A2 BR PI0919065 A2 BRPI0919065 A2 BR PI0919065A2 BR PI0919065 A BRPI0919065 A BR PI0919065A BR PI0919065 A BRPI0919065 A BR PI0919065A BR PI0919065 A2 BRPI0919065 A2 BR PI0919065A2
Authority
BR
Brazil
Prior art keywords
claudin
monoclonal antibodies
virus infection
inhibiting hepatitis
hepatitis
Prior art date
Application number
BRPI0919065A
Other languages
English (en)
Inventor
Catherine Schuster
Fritz Grunert
John Thompson
Thomas Baumert
Original Assignee
Genovac
Inserm Inst De La Santé Et De La Rech
Univ Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genovac, Inserm Inst De La Santé Et De La Rech, Univ Strasbourg filed Critical Genovac
Publication of BRPI0919065A2 publication Critical patent/BRPI0919065A2/pt
Publication of BRPI0919065B1 publication Critical patent/BRPI0919065B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0919065-1A 2008-09-25 2009-09-25 Anticorpos monoclonais anti-claudin-i para a inibição de infecção por vírus de hepatite c BRPI0919065B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08305597 2008-09-25
EP08305597.0 2008-09-25
PCT/EP2009/062449 WO2010034812A1 (en) 2008-09-25 2009-09-25 Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis c virus infection

Publications (2)

Publication Number Publication Date
BRPI0919065A2 true BRPI0919065A2 (pt) 2015-12-15
BRPI0919065B1 BRPI0919065B1 (pt) 2021-09-21

Family

ID=40352777

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919065-1A BRPI0919065B1 (pt) 2008-09-25 2009-09-25 Anticorpos monoclonais anti-claudin-i para a inibição de infecção por vírus de hepatite c

Country Status (10)

Country Link
US (1) US8518408B2 (pt)
EP (1) EP2328933B1 (pt)
JP (1) JP5698137B2 (pt)
KR (1) KR101698015B1 (pt)
CN (1) CN102224171B (pt)
BR (1) BRPI0919065B1 (pt)
CA (1) CA2738027C (pt)
ES (1) ES2529511T3 (pt)
WO (1) WO2010034812A1 (pt)
ZA (1) ZA201102112B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007248493B2 (en) 2006-05-04 2010-09-30 The Rockefeller University HCV coreceptor and methods of use thereof
EP2575885A1 (en) 2010-05-25 2013-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
JP6393875B2 (ja) * 2013-02-28 2018-09-26 公益財団法人ヒューマンサイエンス振興財団 抗体
EP2778126A1 (en) 2013-03-15 2014-09-17 Clariant International Ltd. Lithium transition metal phosphate secondary agglomerates and process for its manufacture
WO2014179716A2 (en) * 2013-05-03 2014-11-06 Emmetrope Ophthalmics Llc IDENTIFICATION AND ISOLATION OF HUMAN CORNEAL ENDOTHELIAL CELLS (HCECs)
JP2016525558A (ja) * 2013-08-02 2016-08-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 結腸直腸ガンの処置に使用するための抗クローディン1抗体
EP3027648A1 (en) * 2013-08-02 2016-06-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-claudin 1 antibodies and uses thereof
US10746738B2 (en) * 2015-02-27 2020-08-18 The Regents Of The University Of Michigan Claudin-1 peptide reagents and methods
EP3070103A1 (en) * 2015-03-19 2016-09-21 Institut Hospitalier Universitaire De Strasbourg Anti-Claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma
CN114907483B (zh) * 2016-03-22 2024-07-26 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
US11170872B2 (en) 2019-11-05 2021-11-09 Apeel Technology, Inc. Prediction of latent infection in plant products
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
EP4433042A4 (en) * 2021-11-18 2025-10-15 Univ Nebraska NOVEL CLAUDIN-1 INHIBITORS FOR THERAPEUTIC INTERVENTION
US20250179170A1 (en) 2022-03-08 2025-06-05 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
EP4532550A1 (en) 2022-06-01 2025-04-09 Alentis Therapeutics AG Use of anti-claudin-1 antibodies to treat cholangiocarcinoma
CN120076826A (zh) 2022-06-01 2025-05-30 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体治疗胆管病的用途
CN115850502A (zh) * 2022-07-14 2023-03-28 清华-伯克利深圳学院筹备办公室 蛋白酶响应的gpcr受体及其应用
JP2025533015A (ja) 2022-09-30 2025-10-03 アレンティス セラピューティクス アクチェンゲゼルシャフト 薬物抵抗性肝細胞癌の処置
CN121605309A (zh) 2023-03-23 2026-03-03 阿伦蒂斯治疗股份公司 使用抗紧密连接蛋白-1抗体的癌症治疗的生物标志物
WO2025224337A1 (en) 2024-04-26 2025-10-30 Alentis Therapeutics Ag Anti-cldn1 antibody-drug conjugates comprising exatecan and methods of use thereof
WO2025224335A1 (en) 2024-04-26 2025-10-30 Alentis Therapeutics Ag Anti-cldn1 antibody-drug conjugates comprising mmae and methods of use thereof
WO2026057702A1 (en) 2024-09-12 2026-03-19 Alentis Therapeutics Ag Claudin-1/egfr bispecific antibodies
WO2026057723A1 (en) 2024-09-12 2026-03-19 Alentis Therapeutics Ag Claudin-1/egfr bispecific antibodies for targeted degradation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044384C (zh) * 1994-08-25 1999-07-28 中国药品生物制品检定所 抗丙型肝炎病毒抗原单克隆抗体细胞株建立及其单克隆抗体
CN1089802C (zh) * 1998-07-31 2002-08-28 中国药品生物制品检定所 抗丙型肝炎病毒非结构区4抗原的单克隆抗体细胞株及其单克隆抗体
EP1167387A1 (en) 2000-06-23 2002-01-02 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
AU750296B2 (en) * 2000-06-23 2002-07-11 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
AU2007248493B2 (en) * 2006-05-04 2010-09-30 The Rockefeller University HCV coreceptor and methods of use thereof

Also Published As

Publication number Publication date
WO2010034812A1 (en) 2010-04-01
JP2012503632A (ja) 2012-02-09
CA2738027C (en) 2018-12-04
KR20110061634A (ko) 2011-06-09
US20110236347A1 (en) 2011-09-29
ZA201102112B (en) 2012-07-25
CA2738027A1 (en) 2010-04-01
CN102224171A (zh) 2011-10-19
US8518408B2 (en) 2013-08-27
JP5698137B2 (ja) 2015-04-08
CN102224171B (zh) 2015-03-11
ES2529511T3 (es) 2015-02-20
KR101698015B1 (ko) 2017-01-19
BRPI0919065B1 (pt) 2021-09-21
EP2328933A1 (en) 2011-06-08
EP2328933B1 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
BRPI0919065A2 (pt) anticorpos monoclonais anti-claudin-1 para a inibição de infecção por virus de hepatite c
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
IL205795A0 (en) Hepatitis c virus antibodies
IL209499A0 (en) Monoclonal antibodies having homosubtype cross - neutralization properties against influenza a viruses subtype h1
PT2274335E (pt) Anticorpos monoclonais capazes de reagirem com diversos subtipos de vírus a da gripe
BRPI0919250A2 (pt) métodos para a purificação de vírus
CY2015012I1 (el) Αναστολεις του ιου της ηπατιτιδας c
ATE555109T1 (de) Hepatitis-c-virus-hemmer
DK2066695T3 (da) Anti-myostatin-antistoffer
CY2015004I1 (el) Αναστολεις του ιου της ηπατιτιδας c
IL239023A0 (en) Neutralizing antibodies to influenza viruses
DK2044121T3 (da) Glyco-konstruerede antistoffer
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
SMT201700083B (it) Anticorpi monoclonali
BRPI1010506A2 (pt) "inibidores do vírus da hepatite c"
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
EP2331125A4 (en) IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
BRPI0907733A2 (pt) Inibidores do vírus da hepatite c
BRPI0809600A2 (pt) vírus atenuado útil para vacinas
CR20170001A (es) Anticuerpos anti factor d humanizados
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
DK3339865T3 (da) Assay for jc-virus-antistoffer
BRPI0909633A2 (pt) anticorpos anti-tyrp1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.